Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial

According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…

Continue Reading Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial
Patient Centricity Helps Facilitate The Introduction of New Therapies for Rare Diseases
stevepb / Pixabay

Patient Centricity Helps Facilitate The Introduction of New Therapies for Rare Diseases

According to a story from Pharmaphorum, there are a number of new treatments that have been introduced or have seen major strides in development over the last year. More patient…

Continue Reading Patient Centricity Helps Facilitate The Introduction of New Therapies for Rare Diseases
Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything
1662222 / Pixabay

Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Patient Worthy. According to a story from Vox, a review of over…

Continue Reading Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything
ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
TeroVesalainen / Pixabay

ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation

According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…

Continue Reading ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial
931527 / Pixabay

ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial

According to a story from globenewswire.com, the biotechnology company Wave Life Sciences Ltd. recently announced that the tolerability and safety data from its Phase 1 clinical trial of its investigational therapy…

Continue Reading ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial
Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU
Capri23auto / Pixabay

Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

According to a story from Market Screener, the drug developer Albireo Pharma, Inc., recently announced that its investigational product candidate A4250 has earned Orphan Drug designation from the European Commission.…

Continue Reading Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU
Device Allows Monitoring of Lung Function at Home For Duchenne Muscular Dystrophy Patients
Myriams-Fotos / Pixabay

Device Allows Monitoring of Lung Function at Home For Duchenne Muscular Dystrophy Patients

According to a story from EurekAlert!, monitoring lung function is an important role of managing Duchenne muscular dystrophy and other diseases that can cause wasting of the respiratory muscles. Many…

Continue Reading Device Allows Monitoring of Lung Function at Home For Duchenne Muscular Dystrophy Patients